“…Estrogen and progesterone, in particular, are known to a ect most components that contribute to urethral closure in many ways, such as biomechanical softening of the tissues, interaction with estrogen receptors, modi®cation of adrenergic receptor density and innervation, changes to electrophysiological properties of smooth muscle, inhibition of extraneuronal uptake of catecholamines, modi®cation of cholinergic responses and interaction with prostaglandins. 2,11 In clinical practice, however, the reported e ects of estrogen treatment, in terms of cure rates and urethral pro®le measurements, are con¯icting. 3,4,12,13 These aspects con®rm, as is known, that UPP is of limited practical value in studying continence or in the follow-up of incontinent patients undergoing estrogen therapy.…”